Having trouble accessing articles? Reset your cache.

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

EMA's CHMP recommended a basket of approvals and label extensions on Nov. 16, including the first all-oral treatment for African trypanosomiasis (sleeping sickness). The agency issued no negative opinions in its monthly roundup.

The agency backed fexinidazole, an antiprotozoal nitroimidazole, from Sanofi (Euronext:SAN; NYSE:SNY) as the first oral therapy sufficient

Read the full 491 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE